{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:40Z","timestamp":1786119160762,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/md.0b013e31815d108c","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T20:30:42Z","timestamp":1236198642000},"page":"344-354","source":"Crossref","is-referenced-by-count":27,"title":["Management of Hypereosinophilic Syndrome"],"prefix":"10.1097","volume":"86","author":[{"given":"Issa J.","family":"Dahabreh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Voulgarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210309","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"R2-4-20210309","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"R3-4-20210309","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000331970205300414","article-title":"Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy---case report and literature review.","volume":"53","author":"Baratta","year":"2002","journal-title":"Angiology"},{"key":"R4-4-20210309","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI109978","article-title":"Comparison of human eosinophils from normals and patients with eosinophilia.","volume":"66","author":"Bass","year":"1980","journal-title":"J Clin Invest"},{"key":"R5-4-20210309","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/56.1.24","article-title":"Quantitation of bone marrow reticulin---a normal range.","volume":"56","author":"Bauermeister","year":"1971","journal-title":"Am J Clin Pathol"},{"key":"R6-4-20210309","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2003.04195.x","article-title":"The eosinophilias, including the idiopathic hypereosinophilic syndrome.","volume":"121","author":"Brito-Babapulle","year":"2003","journal-title":"Br J Haematol"},{"key":"R7-4-20210309","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0091-6749(94)90348-4","article-title":"Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa.","volume":"94","author":"Butterfield","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"R8-4-20210309","first-page":"27","article-title":"A morphometric study of normodense and hypodense human eosinophils that are derived in vivo and in vitro.","volume":"137","author":"Caulfield","year":"1990","journal-title":"Am J Pathol"},{"key":"R9-4-20210309","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002770050434","article-title":"Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases.","volume":"77","author":"Ceretelli","year":"1998","journal-title":"Ann Hematol"},{"key":"R10-4-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"R11-4-20210309","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med"},{"key":"R12-4-20210309","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"R13-4-20210309","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"R14-4-20210309","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"R15-4-20210309","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00062752-200701000-00008","article-title":"Diagnosis and treatment of hypereosinophilic syndromes.","volume":"14","author":"Fletcher","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"R16-4-20210309","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R17-4-20210309","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.coi.2005.09.008","article-title":"The hypereosinophilic syndromes: still more heterogeneity.","volume":"17","author":"Gleich","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"R18-4-20210309","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate.","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"R19-4-20210309","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"R20-4-20210309","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.","volume":"19","author":"Gotlib","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"R21-4-20210309","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"R22-4-20210309","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.22920","article-title":"A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.","volume":"110","author":"Kalac","year":"2007","journal-title":"Cancer"},{"key":"R23-4-20210309","first-page":"214","article-title":"Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.","volume":"209-","author":"Klion","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R24-4-20210309","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"R25-4-20210309","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"R26-4-20210309","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"R27-4-20210309","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases.","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"key":"R28-4-20210309","first-page":"173","article-title":"A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene.","volume":"1","author":"McCarthy","year":"1992","journal-title":"Diagn Mol Pathol"},{"key":"R29-4-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","article-title":"Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.","volume":"85","author":"Muller","year":"2006","journal-title":"Ann Hematol"},{"key":"R30-4-20210309","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"R31-4-20210309","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"R32-4-20210309","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"R33-4-20210309","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"R34-4-20210309","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders.","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"R35-4-20210309","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome.","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"key":"R37-4-20210309","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-4 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"R38-4-20210309","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V94.3.994.415k26_994_1002","article-title":"T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia.","volume":"94","author":"Roufosse","year":"1999","journal-title":"Blood"},{"key":"R39-4-20210309","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol"},{"key":"R40-4-20210309","first-page":"2444","article-title":"Chromosome banding analysis, FISH and RT-PCR performed in parallel in hypereosinophilic syndrome establishes the diagnosis of chronic eosinophilic leukemia in 22% of cases: a study on 40 patients. Abstract.","volume":"104","author":"Schoch","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R41-4-20210309","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V58.5.1021.1021","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.","volume":"58","author":"Schooley","year":"1981","journal-title":"Blood"},{"key":"R42-4-20210309","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"key":"R43-4-20210309","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"R44-4-20210309","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \"atypical\" myeloproliferative disorders and myelodysplastic syndromes.","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"R45-4-20210309","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2005.02.006","article-title":"Anti-IL-5 and hypereosinophilic syndromes.","volume":"115","author":"Sutton","year":"2005","journal-title":"Clin Immunol"},{"key":"R46-4-20210309","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0025-6196(11)62962-5","article-title":"Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment.","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R47-4-20210309","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4065\/81.4.553","article-title":"Atypical myeloproliferative disorders: diagnosis and management.","volume":"81","author":"Tefferi","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R48-4-20210309","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic.","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"R49-4-20210309","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"R50-4-20210309","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome.","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"R51-4-20210309","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ajh.20423","article-title":"Hypereosinophilic syndrome: an update.","volume":"80","author":"Wilkins","year":"2005","journal-title":"Am J Hematol"},{"key":"R52-4-20210309","first-page":"531","article-title":"Altered density, metabolism and surface receptors of eosinophils in eosinophilia.","volume":"47","author":"Winqvist","year":"1982","journal-title":"Immunology"},{"key":"R53-4-20210309","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1346-8138.2000.tb02131.x","article-title":"Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review.","volume":"27","author":"Yoon","year":"2000","journal-title":"J Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e31815d108c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:42:41Z","timestamp":1786038161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-200711000-00004"}},"subtitle":["A Prospective Study in the Era of Molecular Genetics"],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e31815d108c","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}